

A Novel Structural Framework for $\alpha_{1A/D}$ -Adrenoceptor Selective Antagonists Identified Using Subtype Selective Pharmacophores

Emily S. Stoddart^{1†}, Sevandi Senadheera¹, Iain J. A. MacDougall², Renate Griffith^{1,2}, Angela M. Finch^{1*}

1 Department of Pharmacology, School of Medical Sciences, University of New South Wales, Kensington, New South Wales, Australia, **2** School of Environmental and Life Sciences, The University of Newcastle, Ourimbah, New South Wales, Australia

Abstract

In this study four and five-feature pharmacophores for selective antagonists at each of the three α_1 -adrenoceptor (AR) subtypes were used to identify novel α_1 -AR subtype selective compounds in the National Cancer Institute and Tripos LeadQuest databases. 12 compounds were selected, based on diversity of structure, predicted high affinity and selectivity at the α_{1D} - subtype compared to α_{1A} - and α_{1B} -ARs. 9 out of 12 of the tested compounds displayed affinity at the α_{1A} and α_{1D} -AR subtypes and 6 displayed affinity at all three α_1 -AR subtypes, no α_{1B} -AR selective compounds were identified. 8 of the 9 compounds with α_1 -AR affinity were antagonists and one compound displayed partial agonist characteristics. This virtual screening has successfully identified an $\alpha_{1A/D}$ -AR selective antagonist, with low μ M affinity with a novel structural scaffold of an isoquinoline fused three-ring system and good lead-like qualities ideal for further drug development.

Citation: Stoddart ES, Senadheera S, MacDougall IJA, Griffith R, Finch AM (2011) A Novel Structural Framework for $\alpha_{1A/D}$ -Adrenoceptor Selective Antagonists Identified Using Subtype Selective Pharmacophores. PLoS ONE 6(5): e19695. doi:10.1371/journal.pone.0019695

Editor: Franca Fraternali, Kings College, London, United Kingdom

Received: December 9, 2010; **Accepted:** April 14, 2011; **Published:** May 10, 2011

Copyright: © 2011 Stoddart et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by a UNSW, Faculty Research Grant <http://www.unsw.edu.au>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: angela.finch@unsw.edu.au

† Current address: Garvan Institute, Darlinghurst, New South Wales, Australia

Introduction

The α_1 -adrenoceptors (ARs) are members of the G-protein-coupled receptor (GPCR) superfamily, which share a conserved structure of seven transmembrane helices [1]. To date, three different α_1 -AR subtypes, namely α_{1A} -, α_{1B} - and α_{1D} -ARs, have been cloned and characterized [2]. Like other ARs, the α_1 -ARs mediate the actions of the endogenous catecholamines norepinephrine and epinephrine [2]. The α_1 -ARs' primary function is in the contraction of smooth muscle in blood vessels, lower urinary tract and prostate [3,4]. The α_1 -ARs also have functional roles in the central nervous system [5,6,7] and the heart [8]. However, assigning distinct physiological roles to the α_1 -AR subtypes has been restricted by the absence of highly potent and selective ligands devoid of ancillary pharmacology. Ligands that can discriminate between α_1 -AR subtypes based on 100–1000 fold differences in affinity would therefore greatly enhance the task of establishing the distribution and physiological functions of the individual α_1 -AR subtypes.

The specificity of α_1 -AR subtype selective antagonists towards their intended target is a crucial issue due to similarity in receptor structure within the biogenic amine GPCRs [9]. Consequently, many non-subtype selective α_1 -AR antagonist therapeutics used for the treatment of hypertension and benign prostatic hypertension (BPH) are associated with side effects such as increased incidence of heart failure, orthostatic hypotension, erectile dysfunction and dizziness [10]. The development of ligands with enhanced subtype selectivity

therefore holds promise for therapeutics with decreased incidence of side effects.

Although the α_{1A} -AR is the most commonly targeted subtype for the treatment of BPH, the α_{1D} -AR may also be considered a suitable target for both BPH and hypertension. α_{1D} -AR knockout mice display a reduction of systolic and arterial blood pressure [11] and increased blood pressure following dietary salt-loading [12,13]. The α_{1D} -AR is also the predominant subtype in the human bladder detrusor [14] and pharmacological studies using the α_{1D} -AR selective antagonist BMY7378 and the selective $\alpha_{1A/D}$ -AR drug tamsulosin indicate α_{1D} -AR blockade improves the lower urinary tract symptoms of BPH [15]. A selective α_{1D} -AR antagonist may thus have therapeutic potential for the treatment of hypertension and BPH. It is therefore the aim of our research to identify a structurally novel antagonist characterized by high affinity and selectivity towards the α_{1D} -AR compared to α_{1A} - and α_{1B} -ARs, and other biogenic amine GPCRs.

Recently we reported four and five-feature antagonist pharmacophores for the α_{1A} -, α_{1B} - and α_{1D} -ARs, that were developed using training sets of subtype selective antagonists [9]. These training sets were compiled from published affinity data (K_i values from competition assays using recombinant receptors expressed in cell lines) for as wide a range of structural classes of antagonists as was possible. For α_{1A} and α_{1D} pharmacophores only those compounds that exhibited >100-fold selectivity over α_{1B} and >40-fold selectivity over the other subtype (as calculated by the ratio of K_i values) were included. A set of conformations for each compound in each training set was also generated within the

pharmacophore development program Catalyst. As described in our publication [9], Catalyst generates predictive pharmacophores by essentially a three dimensional pattern matching algorithm and extensive statistical analysis. The resulting pharmacophore hypotheses were extensively analysed and validated and finally reduced to one pharmacophore model for each of the three α_1 -ARs. The α_{1A} pharmacophore consists of four features, describing a hydrogen bond acceptor (HBA), a hydrophobic aliphatic (Hal) and a hydrophobic aromatic group (Har), and a basic amine (PI). The training set for this pharmacophore included the two classes of antagonists as described by Klabunde and Evers [16], as well as structurally different compounds, which fitted into neither classification. The resultant pharmacophore was, however, weighted towards the class I antagonists, as they show higher selectivity and affinity than other antagonists. The α_{1B} pharmacophore was generated from antagonists showing selectivity over the other two subtypes, which were predominantly prazosin analogues. This pharmacophore did not include a basic amine feature, as may have been expected, but included 2HBA, Har and Hal features. A five-feature pharmacophore was generated for α_{1D} antagonists. The pharmacophore consisted of HBA, 2Hal, Har and PI features. The training set was heavily populated with analogues of BMY-7378, as these compounds were the only antagonists available which exhibit the appropriate type of selectivity. Despite this limitation of the training set, the pharmacophore was able to accurately predict the affinities of structurally distinct antagonists within a test set.

In this study, use of these pharmacophores in virtual screening of the National Cancer Institute and Tripos LeadQuest compound databases has identified 12 compounds with predicted high affinity and selectivity for the α_{1D} -AR. 9 of the 12 isolated compounds displayed affinity at the α_{1A} and α_{1D} -AR subtypes, and all compounds with α_1 -AR affinity displayed negative efficacy. A lead compound with $\alpha_{1A/D}$ -AR selectivity and a novel structural scaffold of an isoquinoline fused three-ring system was identified for future drug development projects.

Materials and Methods

Compounds **1–6** were purchased from Tripos, Inc. (England) and compounds **7–12** were obtained via the Developmental Therapeutics Program of the National Cancer Institute (USA) (<http://dtp.cancer.gov/>). Drugs were solubilised in dimethyl sulfoxide (DMSO) at 10 mM and stored at -80°C . (-)-Epinephrine, (-)-norepinephrine, phentolamine hydrochloride, lithium chloride (LiCl) and \pm -propranolol were purchased from Sigma-Aldrich. [^3H]Prazosin (85 Ci mmol^{-1}) was from Perkin Elmer and *myo*-[^3H]-Inositol (13 Ci mmol^{-1}) was from Amersham. AG 1-X8 resin (100–200 mesh, formate form) was from Bio-Rad. Chemicals for buffered solutions (HEPES, EGTA and MgCl_2) were obtained from Sigma-Aldrich. Other chemicals used were of the highest purity available.

In Silico Screening

The chemical databases NCI2000 (238,819 compounds) and Tripos' LeadQuest Sample GPCR subset (3040 compounds) were searched in Catalyst version 4.11 (Accelrys Inc, San Diego, USA) using four and five feature subtype specific pharmacophores that we have previously developed [9]. The NCI2000 database was included with the Catalyst installation. The Tripos' LeadQuest Sample GPCR subset was acquired from JPRTechnologies as an .sd file. The .sd file was imported into Catalyst. This process included generating a set of conformations for each molecule in the database. Each search was performed with the "Best flexible"

search option with no maximum limit on the number of hits returned. This search option performs a flexible fit for each conformation of each molecule in the database against the pharmacophore. Unique hits for each subtype were determined using the Boolean operator 'OR' provided in Catalyst, for example the hitlists after searching the NCI2000 database with the three pharmacophores for α_{1A} -, α_{1B} - and α_{1D} -ARs were compared to each other and only unique hits (hits found only in one of the three lists) were kept. Estimates of fit were determined individually for each compound using the 'Rigid' fit option after 'Best' conformational searching, with the number of features allowed to miss set to one.

Cell Culture and Transient Transfection

COS-1 cells (American Type Culture Collection, Manassas, VA) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) heat inactivated fetal bovine serum (FBS), $100\ \mu\text{g ml}^{-1}$ penicillin and $100\ \mu\text{g ml}^{-1}$ streptomycin. Cells were maintained and passaged upon reaching confluence by standard cell culture techniques. pMT4 plasmids containing rodent α_1 -AR (a kind gift from Prof R Graham, Victor Chang Cardiac Research Institute, Australia) were used to transfect cells. Transient expression in COS-1 cells was accomplished using two techniques; the diethylaminoethane-dextran (DEAE-dextran) and Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) methods. Briefly, the DEAE-dextran method involved washing of cells with phosphate buffered saline (PBS), followed by the addition of the DNA mixture ($12\text{--}25\ \mu\text{g}/4\times 10^6$ cells) in DEAE-dextran ($10\ \text{mg ml}^{-1}$) to cells at 60–80% confluency. Following a 3 h incubation, a PBS wash with 10% DMSO was used to shock the cells. Cells were harvested 72 h post transfection. For the Lipofectamine 2000 method, cells were incubated for 12 h with Opti-MEM (GIBCO BRL, Gaithersburg, MD, USA) containing Lipofectamine 2000.

Membrane Preparation

Membranes were prepared as described previously [17]. Briefly, COS-1 cells were transiently transfected using the DEAE-dextran method. Cells were homogenized with a Dounce homogenizer and nuclear debris was removed by centrifugation at $1260\times g$ for 5 min. The membranes were resuspended in HEM buffer (20 mM HEPES, pH 7.4, 1.4 mM EGTA, and 12.5 mM MgCl_2) containing 10% (v/v) glycerol and stored at -80°C until use. Protein concentration was determined using Bradford reagent (Sigma, St Louis, MO, USA).

Ligand Binding Assay

Competition binding reactions contained HEM buffer, 200 pM of [^3H]Prazosin, COS-1 membranes, and increasing amounts of unlabelled National Cancer Institute or Tripos LeadQuest compounds in a total volume of 200 μL . In saturation binding experiments, membranes in HEM buffer were incubated with various concentrations of [^3H]Prazosin in a total volume of 200 μL . For all binding experiments, the reaction mixture was incubated for 1 h at room temperature, stopped by the addition of 4°C PBS and filtered with a Brandel cell harvester (Gaithersburg, MD, USA) on GF/C filters. Nonspecific binding was defined as binding in the presence of 100 μM phentolamine hydrochloride.

Phosphatidylinositol Hydrolysis Assay

Accumulation of [^3H] inositol phosphates (IPs) was determined as described previously [18]. Briefly, COS-1 cells were transiently transfected with α_{1A} , α_{1B} and α_{1D} -AR pMT4 plasmids using the


Lipofectamine method. 24 h after transfection, cells were seeded into 96 well plates and labelled overnight with $20 \mu\text{Ci ml}^{-1}$ [^3H]myo-inositol in inositol free DMEM supplemented with 5% charcoal stripped FBS. Cells were washed twice with inositol free DMEM, and incubated in inositol free DMEM for 2 h at 37°C . Cells were treated for 20 minutes with LiCl (20 mM) and propranolol ($20 \mu\text{M}$) in the presence or absence of tested compounds. Agonists were then added for 30 min, and the reaction was terminated by addition of 0.4 M formic acid. Cells were lysed by freeze thawing twice and were applied to AG 1-X8 columns. Total IPs were eluted with 1 M ammonium formate in 0.1 M formic acid. 200 μL of eluted sample was diluted with 1 mL reverse osmosis water and 5 mL Ultimaflow scintillation fluid (Perkin Elmer), and were counted in a liquid scintillation counter.

Data analysis

Nonlinear regression analysis of saturation and competition binding assay data was performed using the noniterative curve fitting program GraphPad Prism (San Diego, CA, USA). Inhibition constants (K_i) were determined by transformation of the program-calculated IC_{50} (concentration of ligand resulting in 50% inhibition of [^3H]prazosin) value using the Cheng-Prusoff equation. The competitive binding data for each ligand was tested for both one and two -site binding. Subsequently a one-site binding model was determined as the appropriate form of analysis for all binding data. Receptor densities (B_{max}) and the dissociation constant (K_D) for [^3H]prazosin were calculated using the specific binding of the radioligand. Statistically significant differences ($p < 0.05$) in the affinities of compounds were determined using one

Triplos Drug Discovery

Compound Database Code



National Cancer Institute

Compound Database Code




Figure 1. Compound numbers, database codes and structures of selected hits. Compounds were selected based on diversity and novelty of structure, predicted affinity and selectivity for the α_{1D} -AR as well as availability from the Triplos LeadQuest aminergic GPCR and National Cancer Institute 2000 database. The stereochemistry of compounds **1**, **2**, **3**, **6**, **7**, **8**, **10** and **11** is not known. doi:10.1371/journal.pone.0019695.g001

way ANOVA and Student-Newman-Keuls multiple comparison test.

Results

Database screening

The published α_1 AR pharmacophores for subtype selective antagonists were used to search the NCI2000 and the aminergic GPCR subset of Tripos' LeadQuest databases in Catalyst. The NCI2000 database contains 238,819 compounds, and the LeadQuest GPCRDB has 3040 compounds. In each case the entire database was searched with each subtype's pharmacophore using the "best flexible" search option.

Searching the NCI2000 database returned 7630 hits for α_{1A} , 49386 hits for α_{1B} and 3746 hits for α_{1D} . In order to extract compounds that were returned as hits by only one of the three pharmacophores (unique hits), Boolean operators were used in Catalyst. Using this method it was determined that there were 1866 unique α_{1A} hits (0.78% of the whole database), 37746 unique α_{1B} hits (15.81%) and 446 unique α_{1D} hits (0.19%). It is interesting that substantially more hits were returned by the α_{1B} pharmacophore than by α_{1A} and α_{1D} . This may well be due to the 'positive ionisable' (PI) features of the α_{1A} and α_{1D} pharmacophores being more restrictive in terms of database searching. The PI feature in Catalyst is used to describe an atom which is expected to be positively charged at physiological pH. In the case of ligands at adrenergic receptors, this is usually a basic nitrogen atom.

All unique hits were fitted to the pharmacophores to estimate their affinities at each α_1 -AR subtype. The α_{1A} -AR pharmacophore returned 11 compounds with predicted picomolar activity. Many of the top compounds exhibited three fused rings, one compound (NCI0025463) had six fused rings. The α_{1B} pharmacophore returned 25 hits with predicted affinities in the picomolar range. Many of the returned hits were structurally similar to cyclazosin, a

known α_{1B} selective ligand, displaying fused rings with substituents on analogous ring atoms. The α_{1D} pharmacophore returned a number of low nanomolar unique hitters with a variety of structures. Compound NCI0009677 is an adrenaline analogue with two long carbon chains. Two hits (NCI0169489 and NCI0167773) have a fused ring system similar to the compounds boldine and IQC, which have been previously investigated for their activity at the ARs [19].

The GPCR subset of the Tripos LeadQuest database contains compounds which fit a general pharmacophore of a basic nitrogen and an aromatic centre. Our pharmacophore screen returned 1125 hits for α_{1A} -AR, 2144 hits for α_{1B} -AR and 944 hits for α_{1D} -AR. These hit-lists contained 157 unique α_{1A} -AR hits (5.16%), 732 unique α_{1B} -AR hits (24.1%) and 97 unique α_{1D} -AR hits (3.19%). Of these unique hits 33 of the α_{1A} -AR, 5 of the α_{1B} -AR and 1 of the α_{1D} -AR hits had picomolar predicted affinities. The top hits for α_{1A} -AR were all relatively linear structures and most contained aromatic rings at both ends of the structure and a piperaziny, or similar, central ring. The α_{1B} -AR hits were similar, but had more branching evident in the central parts of the structures. The best α_{1D} -AR hits exhibited a similar structural layout to the α_{1A} -AR hits, but in general were shorter in length.

Six compounds were selected from each of the NCI and LeadQuest GPCR database unique α_{1D} -AR hitlists for *in vitro* testing at the α_1 ARs (Figure 1). The compound selection was based on diversity and novelty of structure (not related to structures found in the training sets, or known to have affinity at adrenergic receptors), predicted affinity and selectivity for the α_{1D} -AR as well as availability.

Evaluation of compounds at cloned α_1 - adrenoceptor subtypes

The selected compounds (Figure 1) were assessed for ligand binding characteristics on membrane-expressed α_1 -ARs ($[^3H]$ Pr

Table 1. Binding affinities for selected pharmacophore hit compounds at the α_1 -adrenoceptors (ARs).

Compound	α_{1A} -AR			α_{1B} -AR			α_{1D} -AR		
	pK_i^a	K_i^b (μM)	n	pK_i^a	K_i^b (μM)	n	pK_i^a	K_i^b (μM)	n
1	5.93±0.02 ^D	1.17	4	5.85±0.02 ^D	1.42	3	6.10±0.07	0.83	4
2	6.31±0.03	0.49	4	5.34±0.04 ^A	4.59	4	4.98±0.24 ^A	18.8	5
3	4.90±0.15	15.1	4	5.02±0.51	24.4	4	5.11±0.09	8.35	4
4	∅	∅	3	∅	∅	3	∅	∅	3
5	∅	∅	3	∅	∅	3	∅	∅	3
6	5.31±0.08	5.22	4	4.87±0.20	17.0	4	5.26±0.10	5.90	4
7	4.83±0.24	20.3	3	4.77±0.39	38.5	3	5.01±0.29	59.0	3
8	4.38±0.13	45.9	3	∅	∅	3	4.31±0.04	48.7	3
9	4.63±0.12	24.5	3	∅	∅	3	4.61±0.26	36.1	3
10	∅	∅	3	∅	∅	3	∅	∅	3
11	5.75±0.14 ^B	2.00	3	4.96±0.12 ^D	11.8	3	5.82±0.1	1.60	3
12	4.51±0.30	45.5	3	∅	∅	3	4.49±0.35	62.4	3

n represents the number of experiments, each performed in triplicate.

∅ represents no binding at concentrations up to 100 μM .

^a pK_i (-Log K_i).

^b K_i (inhibition constants) are the antilog of mean pK_i .

K_i values were calculated according to the equation of Cheng and Prusoff. $K_i = IC_{50}/1 + ([L]/K_D)$ when [L] is the radioligand concentration and K_D its dissociation constant.

^Aindicates significant differences from the α_{1A} -AR ($p < 0.05$).

^Bindicates significant differences from the α_{1B} -AR ($p < 0.05$).

^Dindicates significant differences from the α_{1D} -AR ($p < 0.05$).

doi:10.1371/journal.pone.0019695.t001

zosin K_D : α_{1A} 275 ± 59 ; α_{1B} 200 ± 46 ; α_{1D} 153 ± 33 pM, $n = 3-4$). All competition radioligand binding curves displayed sigmoidal binding with the Hill slope for all experiments not significantly different from 1.0 ($p < 0.05$), suggesting all compounds compete at one site with [3 H]-Prazosin.

With the exception of compounds **4**, **5** and **10**, all compounds displayed affinity for the α_1 -ARs in the micromolar range (Table 1). Moderate affinity ($K_i < 2$ μ M) was exhibited by compound **1** at all α_1 -AR subtypes, with compound **11** also displaying moderate affinity at the α_{1A} - and α_{1D} -ARs. Compound **2** displayed the highest affinity of all compounds with a K_i of 0.49 μ M at the α_{1A} -AR. Six of the nine compounds which had α_1 -AR affinity exhibited selectivity for α_{1A} -AR and/or α_{1D} -AR over α_{1B} -AR (Table 1). The greatest selectivity was displayed by **2** at the α_{1A} -AR, being 10- and 38-fold more selective over the α_{1B} - and α_{1D} -ARs respectively ($p < 0.0005$). Increased selectivity for α_{1A} (7-fold) and α_{1D} (17-fold) compared to α_{1B} ($p < 0.005$) was observed with compound **11**.

Evaluation of the efficacy of compounds at the α_1 -adrenoceptor subtypes

Those compounds displaying α_1 -AR affinity (K_i) at concentrations less than 100 μ M were subsequently screened to determine their efficacy at all α_1 -AR subtypes using a phosphatidylinositol hydrolysis assay. Compounds were administered alone (100 μ M) or prior to the addition of 10 μ M (-)-epinephrine, to screen for agonist or antagonist activity respectively. This dosage of (-)-epinephrine was chosen as it resulted in a sub-maximal inositol phosphate (IP) response.

Across all α_1 -AR subtypes, treatment with compounds alone did not result in changes in IP production compared to that of the control (untreated COS-1 cells expressing the α_1 -AR subtype) ($p > 0.05$, $n = 3$), with the exception of **8**, for which a distinct trend of increased IP production was observed at the α_{1A} - and α_{1D} -ARs.

Four compounds (**1**, **2**, **8** and **11**) were selected for further biological testing with the aim of confirming and characterizing their activity quantitatively in terms of IC_{50} (antagonists) or EC_{50} (agonist) values for the α_{1A} -AR. Criterion for selection of a compound was either an affinity (K_i) of ≤ 5 μ M for the α_{1A} -AR or agonist activity.

Compounds **1**, **2**, and **11** concentration-dependently induced a decrease in intracellular IP accumulation following (-) norepinephrine stimulation at the respective α_1 -AR subtypes (Figure 2). All three antagonists have a similar potency at the α_{1A} -AR (pIC_{50} (M) **11**, 4.88 ± 0.27 , $n = 5$, **1**, 4.60 ± 0.11 , $n = 5$ and **2**, 4.77 ± 0.227 , $n = 4$).

A dose dependent increase in intracellular IP was observed following treatment with compound **8** of COS-1 cells expressing the α_{1A} -AR (pEC_{50} , 5.26 ± 0.15 M ($n = 3$)). Maximal IP production induced by compound **8** was approximately 30% of the (-) norepinephrine control (Figure 3), indicating that this compound is a partial agonist.

Mapping of compound 11 onto the α_1 -adrenoceptor pharmacophores

On the α_{1A} pharmacophore (Figure 4A), **11** only maps to three of the four features, missing the positive ionisable (PI) feature entirely (red sphere, top row) (Figure 4A). This feature represents an atom, such as a basic nitrogen, which is likely to be positively charged at physiological pH. The fit to the hydrogen bond acceptor feature (green) is poor. The poor fit of **11** onto the α_{1A} -AR pharmacophore is consistent with the poor (micromolar) affinity of this compound at this receptor subtype, when compared




Figure 2. Inhibition of norepinephrine induced inositol phosphate (IP) accumulation at α_{1A} -AR. α_{1A} -AR transfected cells labelled overnight with [3 H]-myo-inositol were treated with indicated concentrations (300 μ M – 0.1 μ M) of test compounds, **1** (■), **2** (△), and **11** (○), for 20 min. This was followed by a 30 min. stimulation with 10 μ M (-)-norepinephrine, following which total IP accumulation was determined. Data was normalized against basal COS-1 cell IP production and expressed as a percentage of the (-)-norepinephrine-stimulated maximal IP response of that receptor subtype. The data represented the mean \pm SE of a single experiment ($n = 4-5$), performed in triplicate. doi:10.1371/journal.pone.0019695.g002

to a typically nanomolar antagonist, such as the ones used in the development of the pharmacophore [9]. A similar situation is encountered for α_{1B} (Figure 4B), with only two of the four pharmacophore features mapped. Interestingly, when **11** is fitted onto the α_{1D} pharmacophore (Figure 4C), all five features are mapped, albeit with a poor fit for the hydrogen bond acceptor (green). This leads to the very high predicted affinity of **11** for the α_{1D} -AR.




Figure 3. Inositol phosphate (IP) accumulation in the presence of norepinephrine and compound 8 at the α_{1A} -adrenoceptor (AR). α_{1A} -AR transfected cells were labelled with [3 H]-myo-inositol. Following a 20 min. treatment with lithium chloride (20 mM) and propranolol (20 μ M) the cells were stimulated with the indicated concentrations (300 μ M – 0.1 μ M) of (-) norepinephrine (●) or compound **8** (■) for 30 min. Total inositol phosphate (IP) accumulation was determined as described under "Materials and Methods". Data was normalized against basal COS-1 cell IP production and expressed as a percentage of the (-)-norepinephrine-stimulated maximal IP response. The data represents the mean \pm SE of three separate experiments ($n = 3$), performed in duplicate or triplicate. doi:10.1371/journal.pone.0019695.g003




Figure 4. Mapping of compound 11 onto the α_1 -AR subtype pharmacophores. Pharmacophores for subtype selective antagonists for α_{1A} -AR (A), α_{1B} -AR (B), and α_{1D} -AR (C) with compound 11 fitted onto them are shown. Three-dimensional (left) and two-dimensional (right) representations are shown for clarity. The pharmacophore features are represented by colour-coded spheres (red: positive ionisable; green: hydrogen bond acceptor; very light blue: hydrophobic aromatic; light blue: hydrophobic). These spheres depict location constraints where the feature should be situated on the molecule. For hydrogen bond acceptors, the proposed location of the interacting group on the α_1 -AR is also indicated by a second, larger, green sphere. Only features that are in the correct location ('mapped') are indicated in the two-dimensional images. The predicted binding affinity (K_i) was determined as described in the methods section.
doi:10.1371/journal.pone.0019695.g004

Discussion

We have used pharmacophores to screen 241859 compounds *in silico*, from which 12 compounds were selected based on structural diversity and novelty, predicted high affinity and selectivity for the

α_{1D} -AR. 75% of the tested compounds display affinity below 100 μ M at the α_{1A} and/or α_{1D} -AR subtypes and 50% at the α_{1B} -AR. Furthermore, 25% of compounds have affinity in the low micromolar range ($K_i < 5 \mu$ M) at the α_{1A} -AR, and 17% at the α_{1B} - and α_{1D} -ARs. As these compounds only represent 'hits', it is not

expected at this stage of the drug discovery process that compounds will have affinities comparable to established α_1 -AR ligands such as prazosin, which has a K_i value of approximately 0.1 nM at all α_1 -AR subtypes [20]. Indeed, a recent review of virtual screening by Klebe *et al.*, [21] found that of the around 50 targets addressed by virtual screening, most reported the discovery of ligands with micromolar binding affinities.

The 'hit' rate of 17–25% displayed by our α_1 -AR pharmacophores is comparable to the 'hit' rates achieved using the structure based virtual screening technique of docking at the serotonin 5-HT_{1A} and 5-HT₄, dopamine D₂, chemokine CCR₃ and tachykinin NK₁ receptors [22], for which 'hit' rates varied between 12–21% (K_i values <5 μ M). A similar docking study using an α_1 -AR homology model identified 37 novel antagonists, with an impressive 'hit' rate (K_i values <10 μ M) of 46% [16]. Further, a pharmacophore screen by Aventis to identify antagonists for the urotensin II receptor showed a hit rate of 2% (K_i value cut-off not defined) [23].

The isolation of the α_{1D} -AR selective **1**, α_{1A} -AR selective **2**, and the $\alpha_{1A/D}$ -AR selective compounds **8**, **9**, **11** and **12** indicates that the pharmacophores do contain structural motifs important for α_1 -AR subtype selectivity. Furthermore, as no selective α_{1B} -AR compounds were isolated and 50% of the compounds were α_{1A} and/or α_{1D} -AR selective, this suggests screening the compound libraries using the α_{1B} -AR pharmacophore did successfully identify and eliminate compounds with this characteristic from the pool of compounds.

The inability to distinguish between the α_{1A} - and α_{1D} -AR subtypes reflects the lack of $\alpha_{1A/D}$ -AR selectivity of the training sets used to generate the α_{1A} - and α_{1D} -AR pharmacophores [9]. Compounds available at the time in the literature only exhibited >40-fold selectivity of α_{1A} over α_{1D} -ARs, and therefore it is not expected that compounds isolated by the pharmacophores would display large α_{1A}/α_{1D} selectivity.

α_1 -AR pharmacophores in the literature have been primarily used to screen the affinity of derivatives of established α_1 -AR ligands [24,25,26,27,28]. This approach involves the screening of compounds with narrow structural frameworks that are predetermined to have α_1 -AR affinity, with the purpose of isolating which chemical moieties provide the most advantageous characteristics of affinity and selectivity. In contrast to this, in this study large compound libraries of structurally diverse compounds have been screened, which has the benefit of identifying compounds with novel structural scaffolds. This represents the first attempt to screen diverse compound databases using α_1 -AR pharmacophores, representing a novel approach to the identification of α_1 -AR ligands.

There are currently eight established structural classes of α_1 -AR antagonists. All the compounds possess a central basic nitrogen, but it is the nature of the basic centre, the substitution of aromatic rings and the spatial orientation of chemical groups that determines subtype selectivity profile [29]. Compound **1** contains a piperazine ring motif, which is a common structural motif in α_1 -AR antagonists. There has been extensive research into this class of α_1 -AR antagonists, and analysis of the chemical structures of selective α_1 -AR antagonists indicates that a large group of active compounds contain the N-aryl or N-heteroaryl piperazine motif [30]. Accordingly, progress has been made in terms of understanding the chemical moieties of these derivatives important for α_1 -AR selectivity [28,30], including significant details such as the




Figure 5. Fused ring systems as scaffolds for α_1 -AR antagonists. (A) Discretamine, with the 4-ring berbine motif highlighted in red. (B) Compound, **11**, with the novel fused isoquinoline 3-ring motif highlighted in pink and (C) Boldine, with the 4 ring aporphine motif highlighted in green.”

doi:10.1371/journal.pone.0019695.g005

size and positioning of substituents on the phenyl ring of the arylpiperazine motif [26,31]. Despite this, selectivity against the α_2 -AR [26,30] and the 5-HT_{1A} [28] receptors remain significant issues. Further, a study of more than 2000 compounds known to act at GPCRs that aimed to identify privileged substructures within GPCR ligands, identified the 4-phenyl-piperazine motif as the most frequently occurring, being present in 32 compounds which act at 13 different GPCRs [32]. Therefore, compound **1** does not represent a suitable lead compounds in terms of structural novelty, and potential for subtype selectivity.

Compound **11** however contains a novel fused isoquinoline three-ring system. Whilst fused four-ring motifs are found in berbine derivatives, such as the natural product (–) discretamine [33], and aporphine derivatives [34], both of which display α_1 -AR antagonism, a fused three-ring system has not previously been described for α_1 -AR ligands (Figure 5). Furthermore, the rigid core of compound **11** is an ideal template for developing a more bioactive flexible ligand [35]. Additionally, compound **11** contains few hydrogen bond forming groups and has a low molecular weight (335 Da), facilitating synthetic elaboration to enhance affinity and selectivity. While the free base has a relatively high calculated partition coefficient (clogP 4.9), salts can easily be prepared to enhance aqueous solubility.

We are currently developing a convergent synthesis of compound **11**, allowing synthetic access to the molecule itself, as well as analogues for optimisation. In the absence of crystal structures of the three α_1 -AR subtypes, optimisation will be guided by docking into our previously described homology models [9] based on crystal structures of bovine rhodopsin as well as new models based on a number of new crystal structures of more closely related G-protein coupled receptors which have recently been published [36].

In conclusion, the computer-aided drug discovery ligand-based pharmacophore technique has been established as a powerful alternative virtual screening tool. Compound **11** therefore represents a suitable lead compound for future drug development projects, due to its novel conformationally constrained structure, its “lead-like” properties and desirable affinity, efficacy and selectivity characteristics.

Author Contributions

Conceived and designed the experiments: AMF RG. Performed the experiments: ESS SS IJAM. Analyzed the data: ESS IJAM RG AMF. Wrote the paper: ESS RG AMF.

References

- Eilers M, Hornak V, Smith SO, Konopka JB (2005) Comparison of Class A and D G protein-coupled receptors: Common features in structure and activation. *Biochem* 44: 8959–8975.
- Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, et al. (1995) International Union of Pharmacology. X. Recommendation for nomenclature of α_1 -adrenoceptors: consensus update. *Pharmacol Rev* 47: 267–270.

3. Civantos Calzada B, Aleixandre de Artiñano A (2001) α -adrenoceptor subtypes. *Pharmacol Res* 44: 195–208.
4. Tanoue A, Koshimizu T-a, Tsujimoto G (2002) Transgenic studies of α_1 -adrenergic receptor subtype function. *Life Sci* 71: 2207–2215.
5. Harasawa I, Honda K, Tanoue A, Shinoura H, Ishida Y, et al. (2003) Responses to noxious stimuli in mice lacking α_{1D} -adrenergic receptors. *Neuroreport* 14: 1857–1860.
6. Knauber J, Muller WE (2000) Decreased exploratory activity and impaired passive avoidance behaviour in mice deficient for the α_{1B} -adrenoceptor. *Eur Neuropsychopharmacol* 10: 423–427.
7. Mishima K, Tanoue A, Tsuda M, Hasebe N, Fukue Y, et al. (2004) Characteristics of behavioral abnormalities in α_{1D} -adrenoceptors deficient mice. *Behav Brain Res* 152: 365–373.
8. Zuscik MJ, Chalothorn D, Hellard D, Deighan C, McGee A, et al. (2001) Hypotension, Autonomic Failure, and Cardiac Hypertrophy in Transgenic Mice Overexpressing the α_{1B} -Adrenergic Receptor. *J Bio Chem* 276: 13738–13743.
9. MacDougall IJ, Griffith R (2006) Selective pharmacophore design for α_1 -adrenoceptor subtypes. *J Mol Graph Model* 25: 146–157.
10. ALLHAT (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *J Am Med Assoc* 283: 1967–1975.
11. Tanoue A, Nasa Y, Koshimizu T, Shinoura H, Oshikawa S, et al. (2002) The α_{1D} -adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. *J Clin Invest* 109: 765–775.
12. Chu C-P, Kunitake T, Kato K, Watanabe S, Qiu D-L, et al. (2004) The α_{1D} -adrenergic receptor modulates cardiovascular and drinking responses to central salt loading in mice. *Neurosci Lett* 356: 33–36.
13. Tanoue A, Koba M, Miyawaki S, Koshimizu T, Hosoda C, et al. (2002) Role of the α_{1A} -adrenergic receptor in the development of salt-induced hypertension. *Hypertension* 40: 101–106.
14. Malloy BJ, Price DT, Price RR, Bienstock AM, Dole MK, et al. (1998) α_1 -adrenergic receptor subtypes in human detrusor. *J Urol* 160: 937–943.
15. Schwinn DA, Roehrborn CG (2008) α_1 -Adrenoceptor subtypes and lower urinary tract symptoms. *Int J Urol* 15: 193–199.
16. Klabunde T, Evers A (2005) GPCR antitarget modeling: Pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects. *Chembiochem* 6: 876–889.
17. Perez DM, Piascik MT, Graham RM (1991) Solution-phase library screening for the identification of rare clones: isolation of an α_{1D} -adrenergic receptor cDNA. *Mol Pharmacol* 40: 876–883.
18. Chengalvala M, Kostek B, Frail DE (1999) A multi-well filtration assay for quantitation of inositol phosphates in biological samples. *J Biochem Biophys Methods* 38: 163–170.
19. Bremner JB, Coban B, Griffith R, Groenewoud KM, Yates BF (2000) Ligand design for α_1 adrenoceptor subtype selective antagonists. *Bioorgan Med Chem* 8: 201–214.
20. Ford APDW, Daniels DV, Chang DJ, Gever JR, Jasper JR, et al. (1997) Pharmacological pleiotropism of the human recombinant α_{1A} -adrenoceptor: implications for α_1 -adrenoceptor classification. *Brit J Pharmacol* 121: 1127–1135.
21. Klebe G (2006) Virtual ligand screening: strategies, perspectives and limitations. *Drug Discov Today* 11: 580–594.
22. Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, et al. (2006) An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT_{1A} agonist (PRX-00023) for the treatment of anxiety and depression. *J Med Chem* 49: 3116–3135.
23. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, et al. (2002) Identification of nonpeptidic urotensin ii receptor antagonists by virtual screening based on a pharmacophore model derived from structure–activity relationships and nuclear magnetic resonance studies on urotensin II. *J Med Chem* 45: 1799–1805.
24. Barbaro R, Betti L, Botta M, Corelli F, Giannaccini G, et al. (2001) synthesis, biological evaluation, and pharmacophore generation of new pyridazinone derivatives with affinity toward α_1 - and α_2 -adrenoceptors. *J Med Chem* 44: 2118–2132.
25. Barbaro R, Betti L, Botta M, Corelli F, Giannaccini G, et al. (2002) Synthesis and biological activity of new 1,4-benzodioxan-arylpiperazine derivatives. Further validation of a pharmacophore model for α_1 -adrenoceptor antagonists. *Bioorg Med Chem* 10: 361–369.
26. Betti L, Botta M, Corelli F, Floridi M, Fossa P, et al. (2002) α_1 -Adrenoceptor antagonists. Rational design, synthesis and biological evaluation of new trazodone-like compounds. *Bioorg Med Chem Lett* 12: 437–440.
27. Li M-Y, Tsai K-C, Xia L (2005) Pharmacophore identification of α_{1A} -adrenoceptor antagonists. *Bioorg Med Chem Lett* 15: 657–664.
28. Lopez-Rodriguez ML, Morcillo MJ, Fernandez E, Porras E, Orensanz L, et al. (2001) Synthesis and structure–activity relationships of a new model of arylpiperazines. study of the physicochemical influence of the pharmacophore on 5-HT_{1A}/ α_1 -adrenergic receptor affinity: synthesis of a new derivative with mixed 5-HT_{1A}/D₂ antagonist properties. *J Med Chem* 44: 186–197.
29. Jain KS, Bariwal JB, Kathiravan MK, Phoujdar MS, Sahne RS, et al. (2008) Recent advances in selective α_1 -adrenoreceptor antagonists as antihypertensive agents. *Bioorg Med Chem* 16: 4759–4800.
30. Handzlik J, Maciag D, Kubacka M, Mogilski S, Filipek B, et al. (2008) Synthesis, α_1 -adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phentoin. *Bioorg Med Chem* 16: 5982–5998.
31. Strappaghetti G, Mastrini L, Lucacchini A, Giannaccini G, Betti L, et al. (2008) Synthesis and biological affinity of new imidazo- and indol-arylpiperazine derivatives: Further validation of a pharmacophore model for α_1 -adrenoceptor antagonists. *Bioorg Med Chem Lett* 18: 5140–5145.
32. Klabunde T, Hessler G (2002) drug design strategies for targeting G-protein-coupled receptors. *Chem Bio Chem* 3: 928–944.
33. Ko FN, Guh JH, Yu SM, Hou YS, Wu YC, et al. (1994) (-)-Discretamine, a selective α_{1D} -adrenoceptor antagonist, isolated from *Fissistigma glaucescens*. *Brit J Pharmacol* 112: 1174–1180.
34. Ivorra MD, Valiente M, Martinez S, Madrero Y, Noguera MA, et al. (2005) 8-NH₂-Boldine, an antagonist of α_{1A} and α_{1B} adrenoceptors without affinity for the α_{1D} subtype: Structural requirements for aporphines at α_1 -adrenoceptor subtypes. *Planta Med* 2005, 71(10): 897–903.
35. Bremner JB, Griffith R, Coban B (2001) Ligand design for α_1 -adrenoceptor. *Curr Med Chem* 8: 607–620.
36. Vaidehi N (2010) Dynamics and flexibility of G-protein-coupled receptor conformations and their relevance to drug design. *Drug Discov Today* 15: 951–957.